James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

3 Reasons to Sell Your Netflix Inc (NFLX) Stock Now

Netflix is the name to beat within the on-demand video business, but that doesn't inherently make NFLX stock a must-have investment.

Eli Lilly and Co (LLY) Drug Failure Doesn’t Answer the Bigger Question

Eli Lilly (LLY) may be a bargain after today's plunge, but LLY stock won't be a good Alzheimer's bet anytime in the foreseeable future.

The Dow Jones Is Completely Defying Expectations

The Dow Jones Industrial Average (DJIA) popped past 19,000 on Tuesday, but the pivotal line may end up just being a pivot.

Why Medtronic PLC (MDT), Dycom Industries, Inc. (DY) and Palo Alto Networks Inc (PANW) Are 3 of Today’s Worst Stocks

Dycom Industries (DY), Medtronic PLC (MDT) and Palo Alto Networks (PANW) all reported solid earnings but miserable revenue for last quarter.

This Is the New Reality for Alibaba (BABA) Stock

Alibaba Group Holding Ltd (BABA), once a crowd pleaser, is getting a few dings as the passage of time weighs on Alibaba stock.